Ariad Pharmaceuticals followed last month’s request to the FDA for accelerated approval of the BCR-ABL inhibitor ponatinib with a similar request to the European Medicines Agency.
A new device called MarginProbe may soon be available to help surgeons determine the minimal amount of tissue to be removed during a lumpectomy and reduce re-excision rates.
Researchers have concluded after a large meta-analysis of trials involving more than 29,000 patients that patients taking currently available biologic therapies for rheumatoid arthritis (RA) are not at increased risk of cancer.
Researchers have linked recreational marijuana use to an increased risk of developing germ-cell tumors, a type of testicular cancer that often has a poor prognosis.
Intermittent androgen deprivation was shown to be as effective as continuous therapy in terms of overall survival for men with prostate cancer whose PSA levels were rising after initial or salvage radiotherapy.
A new study found that aspirin use was associated with a reduced risk of prostate cancer mortality in patients previously treated with prostatectomy or radiotherapy.
For the first time, two research groups have sequenced and analyzed the genomes of small-cell lung cancer (SCLC) and identified new gene mutatations that could drive the development of new therapies and the application of existing ones.
The presence of a mutation in the KRAS gene in patients with advanced lung adenocarcinomas was associated with significantly shorter overall survival than patients without the mutation, according to a new study.
A new phase III trial found that first-line erlotinib followed by chemotherapy at disease progression to be significantly inferior to the standard practice of first-line cisplatin-gemcitabine followed by erlotinib.
A study comparing dasatinib to imatinib in patients with chronic myeloid leukemia found that the second-generation TKI dasatinib yielded better remission and molecular response rates than imatinib, but these did not result in better survival outcomes.